DESCRIPTION

DBV Technologies is a global biopharmaceutical company that’s pioneering investigational epicutaneous immunotherapy (EPIT™) to potentially treat millions of people suffering from life-threatening food allergies and other immunological disorders. Starting with peanut, we are investigating food allergy treatments designed to potentially reduce the risk of unpredictable reactions due to accidental peanut exposure. We are actively working with leading immunologists and allergists to develop the EPIT technology platform to provide solutions across a range of conditions where unmet medical needs exist.